SAVOIR: A phase III study of savolitinib versus sunitinib in pts with MET-driven papillary renal cell carcinoma (PRCC).Toni K. Choueiri, Laurence Albigès, Jae‐Lyun Lee et al.|Journal of Clinical Oncology|2020Cited by 5